Serotype Characterization of Streptococcus pneumoniae Identified in Meningitis Cases in Sevral Asian and European Countries

Background. The current epidemiology of pneumococcal meningitis in Ukraine, Georgia and countries of CIS is poorly studied. In order to ensure an effective vaccination strategy and post-vaccination surveillance, we examined the serotype distribution patterns of pneumococcal meningitis in the following regions: European (Ukraine, Belarus), Transcaucasian (Azerbaijan, Armenia, Georgia), and Asian (Uzbekistan, Kyrgyzstan, Kazakhstan). The study was performed within the program for Invasive Bacterial Diseases Sentinel Surveillance implemented in the region by WHO Regional Office for Europe. Methods. Cerebrospinal fluid (CSFs) samples were collected from patients with suspected meningitis at sentinel hospitals throughout all the regions within the period 2007 - 2016. Determination of S. pneumoniae and serogroups/serotypes in positive CSFs was performed using qPCR and mPCR. In total 3013 CSFs were tested: 2764 (91.7%) of them were collected from patients aged under 5 years, 128 (4.2%) from children aged 5 - 18 years and 121 (4.1%) from adults. Results. 6% (188) of CSFs analyzed were positive for S. pneumoniae, The PCR assay used could predict the S. pneumoniae serotypes/ serogroups for 82% (n = 154) of positive CSFs, 16% were not-typeable in our PCR scheme and for 2% serotyping was not performed. In total, 26 different serotypes/serogroups were identified. Serotypes 6A/B (21%), 14 (15%), 19F (10%), 23F (7%), 18 (A/B/C) (4%), 9V/9A (3%) and 4 (3%) were found to be the most prevalent, followed by others with a prevalence of 2% and less(6C/6D, 24(A/B/F), 19A, 5, 3,1,23A,20,2,13,31, 8, 7F/7A, 7C/7B/40, 22F/22A, 21, 15B/15C, 12F/12A/12B/44/46, 11A/11D). Conclusions. The proportion of vaccine serotypes in pneumococcal meningitis cases (vaccine coverage) amounts to 67% for PCV10 and 71% for PCV13 in all the regions, suggesting that the introduction of conjugate vaccines (PCV10 and 13) into National Immunization Programs is feasible. Post-vaccine introduction surveillance supported will be essential. Post-vaccine introduction surveillance and monitoring of changes in serotype S. pneumoniae distribution in cases with invasive pneumococcal disease and in healthy carriers is essential to assess the vaccination effectiveness and to provide a comprehensive picture of the vaccination impact on pneumococcal serotype distribution in the region.

Streptococcus pneumoniae, серотипы, вакцинация, менингит, ВОЗ, ПКВ, Streptococcus pneumoniae, serotypes, vaccination, meningitis, WHO PCV

1. Laboratory Methods for the Diagnosis of Meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae: WHO manual, 2nd edition; WHO/IVB.11.09; 2011.

2. Koroleva M.A. Epidemiological monitoring of purulent bacterial meningitis in Russian Federation. Doctorate of med. sci. diss. Moscow; 2014: 24 (in Russian).

3. Briand C., Levy C., Baumie F., Joao L., Béchet S., Carbonnelle E., et al. Outcomes of bacterial meningitis in children. Lancet. 2010; 10: 317 – 328.

4. stergaard C., Konradsen H.B., Samuelsson S. Clinical presentation and prognostic factors of Streptococcus pneumoniae meningitis according to the focus of infection. BMC Infect. Dis. 2005; 5: 93.

5. Brouwer M.C., Tunkel A.R., van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clinical microbiology reviews. 2010; 23 (3): 467 – 492.

6. Sidorenko S.V., Lobzin Yu.V., Kharit S.M., Koroleva I.S., Tatochenko V.K. Pneumococcal infection and modern possibilities of prevention – an epidemiological review of the situation in the world and Russia. Voprosy sovremennoy terapii. [Questions of modern pediatrics]. 2010; 9 (1): 54 – 61 (in Russian).

7. Sheley J., Willman D., Downen J., Bergman S. Investigation of the Selection and Timing of Pharmacological Therapy in Community-Acquired Bacterial Meningitis. Pharmacy and Therapeutics. 2016; 41 (7): 437 – 441.

8. Butler J. Pneumococcal disease. In: Tuomanen E, Mitchell T, Morrison D., Spratt B. eds. The Pneumococcus. (1st ed.) Washington, DC: American Society for Microbiology; 2004: 148 – 168.

9. Baranov A.A., Namazova-Baranova L.S., Briko N.I., Chuchalin A.G., Tatochenko V.K., Kharit S.R., et al. Vaccinal prevention of pneumococcal infection. Federal clinical guidelines. Moscow. 2015: 24 (in Russian).

10. Kozlov R.S. Pneumococcus: past, present and future. Smolensk: Smolensk State Medical Academy; 2005: 128 (in Russian).

11. Baranov A.A., Namazova L.S., Tatochenko V.K. Pneumococcal infection and related diseases - a major problem of modern health care. Pediatricheskaya farmakologiya. [Pediatric Pharmacology]. 2008; 5 (1): 28 – 33 (in Russian).

12. Vengerov Yu.Ya., M.V. Nagibina, E. P. Mikhalinova, S. E. Razdobarina, T. N. Molotilova, Yu. G. Parkhomenko, et al. Pneumococcal meningitis. The problem of high mortality. Lechashchiy vrach. [Therapist]. 2015; 5: 14 – 18 (in Russian).

13. Backhaus E., Berg S., Andersson R., Ockborn G., Malmström P., Dahl M., et al. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infectious Diseases. 2016; 16: 367.

14. Song J.Y., Nahm M.H., Moseley M.A. Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J. Korean Med Sci. 2013; 28 (1): 4 – 15.

15. Yildirim I., Kimberly M., Pelton S.I. Pneumococcal disease in the era of pneumococcal conjugate vaccine. Infect. Dis. Clin. North Am. 2015; 29 (4): 679 – 697.

16. Alari A., Chaussade H., De Cellès M.D., Le Fouler L., Varon E., Opatowski L. et al. Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis. BMC Medicine 2016; 14: 211.

17. Koroleva I.S., Beloshitskiy G.V., Koroleva M.A., Mel’nikova A.A.. Epidemiological aspects of pneumococcal meningitis in the Russian Federation. Epidemiologiya i Vaktsinoprofilaktika. [Epidemiology & Vaccinal Prevention]. 2016; 15 (5): 6 – 13 (in Russian).

18. Koroleva I.S., Beloshitskiy G.V., Mironov K.O. Characteristics of pneumococcal serotypes isolated from patients with pneumococcal meningitis. Voprosy sovremennoy pediatrii. [Questions of modern pediatrics]. 2012. 11 (4): 122 – 127 (in Russian).

19. del Amo E., Brotons P., Monsonis M., Triviño M., Iñigo M., Selva L. High invasiveness of pneumococcal serotypes included in the new generation of conjugate vaccines. Clin. Microbiol. Infect. 2014; 20 (7): 684 – 689.

20. Pichon B., Ladhani S., Slack M., Segonds-Pichon A., Andrews N., Waight P. et al. Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales. Journal of clinical microbiology. 2013; 51 (3): 820 – 827.

21. Tai S. Streptococcus pneumoniae serotype distribution and pneumococcal conjugate vaccine serotype coverage among pediatric patients in East and Southeast Asia, 2000 – 2014: a Pooled Data Analysis. Vaccines. 2016; 4 (1): 4.

22. Kovtun O.P., Romanenko V.V. The effectiveness of next generation pneumococcal conjugate vaccines in different parts of the world. Voprosy sovremennoy pediatrii. [Questions of modern pediatrics]. 2014; 13 (1): 18 – 25 (in Russian).

23. Tatochenko V., Sidorenko S., Namazova-Baranova L., Mayanskiy N., Kulichenko T., Baranov A., et al. Streptococcus pneumoniae serotype distribution in children in the Russian Federation before the introduction of pneumococcal conjugate vaccines into the National Immunization Program. Expert Review of Vaccines. 2014; 13 (2): 257 – 264 (in Russian).

24. Blumental S., Moïsi JC., Roalfe L., Zancolli M., Johnson M., Burbidge P. et al. Streptococcus pneumoniae serotype 1 burden in the African meningitis belt: exploration of functionality in specific antibodies. Clinical and vaccine immunology. 2015; 22 (4): 404 – 412.

25. Ceyhan M., Dagan R., Sayiner A., Chernyshova L., Dinleyici E.Ç., Hryniewicz W., et al. Surveillance of pneumococcal diseases in Central and Eastern Europe. Hum. Vaccin. Immunother. 2016; 12 (8): 2124 – 2134.

26. Tadzhieva N.U. Improving the diagnosis, treatment and prevention of pneumococcal disease in children. PhD of med. sci. diss. Tashkent; 2016 (in Russian).

27. Davydov A.V., Titov L.P., Klyuyko N.L., Gurinovich V.V. Characteristics of pneumococcal serotypes, isolated from children with acute otitis media and sinusitis. Zdravookhranenie. Minsk. 2016; 3: 12 – 21 (in Russian).

28. Mirnov K.O., Platonov A.E., Kozlov R.S. Identification and serotyping Russian strains of Streptococcus pneumoniae with the methods based on PCR. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. [Clinical microbiology and antimicrobial chemotherapy]. 2011; 13 (4): 304 – 319 (in Russian).

29. Cohen C., Naidoo N., Meiring S., de Gouveia L., von Mollendorf C., Walaza S.. Streptococcus pneumoniae serotypes and mortality in adults and adolescents in South Africa: Analysis of National Surveillance Data, 2003 – 2008. EID. 2016; 22 (2).

30. SR 1.2.036-95. The treatment, storage, transfer and transport of microorganisms I – IV pathogenicity groups (in Russian).

31. Pimenta F.C., Roundtree A., Soysal A., Bakir M., du Plessis M., Wolte N. et al. Sequential triplex real-time pcr assay for detecting 21 pneumococcal capsular serotypes that account for a high global disease burden. J. Clin. Microbiol. 2013; 51 (2): 647 – 652.